Robert Strzinek, DO
Family Medicine · Hurst, TXNPI 1568480457
Payments from drug & device makers
What this record shows
This record is dominated by food and beverage: $1,777 of the $2,836 with a category attached, or 62.6%. 14 manufacturers reported payments, led by Novo Nordisk AS at 48.0% of the total. Reporting peaked in 2019 at $1,764 and has fallen 78.4% since, to $381 in 2025.
Across 77 payments — averaging $36.83 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Novo Nordisk AS$1K
- Novo Nordisk$789
- Amgen$130
- Pfizer$123
- Abbott$116
- Exact Sciences$95
- plus $221 from 8 others
Across 653 payments — averaging $2144.20 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- AbbVie$728K
- Kowa Research Institute, Inc.$179K
- Amgen$141K
- Akcea Therapeutics, Inc.$121K
- Novo Nordisk AS$107K
- Sanofi US Services Inc.$75K
- plus $50K from 5 others
What the payments were for
- Travel & lodging$1,06037%
- Food & beverage$1,77763%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Novo Nordisk AS | 7 | $1,363 |
| Novo Nordisk | 31 | $789 |
| Amgen | 8 | $130 |
| Pfizer | 7 | $123 |
| Abbott | 6 | $116 |
| Exact Sciences | 6 | $95 |
| Lilly USA, LLC | 4 | $67 |
| Bayer | 2 | $38 |
| AstraZeneca | 1 | $24 |
| Biogen | 1 | $23 |
| Eisai Inc. | 1 | $19 |
| Ascensia Diabetes Care US Inc. | 1 | $18 |
| Halozyme Inc | 1 | $16 |
| Boehringer Ingelheim | 1 | $15 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- Ozempic$1,353
How this compares
$2,836 in reported general payments places this provider in the 80th percentile of 8,760 family medicine providers in Texas.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| OzempicSemaglutide | 84 | $134,399 |
| JardianceEmpagliflozin | 17 | $29,996 |
| FarxigaDapagliflozin Propanediol | 19 | $22,255 |
| MounjaroTirzepatide | 17 | $20,086 |
| EliquisApixaban | 24 | $18,016 |
| Tresiba Flextouch U-100Insulin Degludec | 11 | $14,151 |
| Tresiba Flextouch U-200Insulin Degludec | 12 | $10,562 |
| Toujeo Max SolostarInsulin Glargine,hum.Rec.Anlog | 13 | $10,039 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 11 | $9,805 |
| SynthroidLevothyroxine Sodium | 49 | $4,466 |
| PremarinEstrogens, Conjugated | 14 | $3,206 |
| Levothyroxine Sodium | 247 | $2,122 |
| Rosuvastatin Calcium | 172 | $1,823 |
| Gabapentin | 54 | $1,582 |
| Epinephrine | 12 | $1,410 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Novo NordiskOzempic | $789 | $134,39984 claims |
| Boehringer IngelheimJardiance | $15 | $29,99617 claims |
| AstraZenecaFarxiga | $24 | $22,25519 claims |
| PfizerEliquis, Premarin | $123 | $21,22238 claims |
| Lilly USA, LLCMounjaro | $67 | $20,08617 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 80th percentile of 8,760 family medicine providers in Texas.
Other family medicine in Hurst
- Carlos CamposNew Braunfels$1.5M
- Aaron KingSan Antonio$1.1M
- Bradley WassonArlington$734K
- Cynthia BrinsonAustin$402K
- Michael MendezLubbock$368K
- Sang Tae KimAmarillo$368K
- Sumit PerakathuHarlingen$342K
- Joel SolisMcAllen$324K
- Robert CampbellFort Worth$318K
- Jose LedezmaEdinburg$300K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.